Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Director/PDMR Shareholding

1 Mar 2016 10:35

RNS Number : 6255Q
IXICO plc
01 March 2016
 

1 March 2016

IXICO plc Director's dealings

 

1 March 2016, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, announces that it was notified on 1 March 2016 that, on the same day, Susan Lowther, Chief Financial Officer of the Company, purchased 28,366 Ordinary Shares of 1p each in IXICO at a price of 35.25p pence per Ordinary Share. As a consequence of this share purchase, Susan Lowther is beneficially interested in 28,366 Ordinary Shares representing 0.11% of the Company's issued share capital.

 

Enquiries:

 

IXICO plc

+44 20 3763 7499

Derek Hill, CEO

Susan Lowther, CFO

Peel Hunt LLP (Nominated Adviser and Broker)

+44 20 7418 8900

James Steel / Oliver Jackson

Daniel Stewart & Company (Joint Broker)

+44 207 776 6550

Martin Lampshire / David Coffman

FTI Consulting Limited (Investor Relations)

+44 20 3727 1000

Simon Conway / Mo Noonan / Matthew Moss

 

 

Notes to Editors

 

About IXICO

IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

 

The Company's brain health focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, behavioural health, child and adolescent mental health.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBFLFBQXFXBBX
Date   Source Headline
3rd May 20187:00 amRNSPlacing to raise ?5.5 million
4th Apr 20187:00 amRNSAgreement
30th Jan 20187:00 amRNSNew contract in progressive supranuclear palsy
22nd Jan 20183:16 pmRNSResult of AGM
22nd Jan 20187:00 amRNSAGM Statement and Board Changes
11th Dec 20177:00 amRNSFinal Results
28th Nov 20177:00 amRNSStrategic and Operational Update
16th Nov 20177:00 amRNSContract to Deploy Biosensors in Clinical Trial
19th Oct 201710:14 amRNSTrading Statement
4th Oct 20177:00 amRNSNew contract to support Phase II clinical trial
28th Sep 20177:00 amRNSNew contract in Huntington's disease
25th Sep 20177:00 amRNSNew Contract with Biopharmaceutical Company
5th Sep 20177:00 amRNSExtension of a 5 year contract
8th Aug 20174:23 pmRNSDirector/PDMR Shareholding
24th Jul 20177:00 amRNSExpansion of Collaboration with Biogen
18th Jul 20177:00 amRNSIXICO hosts Alzheimer Expert Symposium
5th Jul 20177:00 amRNSNew contract for imaging clinical trial services
22nd May 20177:00 amRNSHalf Yearly Report to 31 March 2017
16th May 20179:57 amRNSNotice of H1 Results
12th Apr 201712:41 pmRNSExercise of share options
29th Mar 20173:30 pmRNSDirector/PDMR Shareholding
29th Mar 20173:30 pmRNSDirector/PDMR Shareholding
29th Mar 20173:30 pmRNSExercise of Share Options
13th Mar 20177:00 amRNSIXICO signs US$1.5m contract
10th Mar 201710:00 amRNSTo present novel sleep measurement technology
9th Feb 20177:00 amRNSGrant of Share Options
30th Jan 201710:28 amRNSResult of AGM
17th Jan 20174:09 pmRNSDirector/PDMR Shareholding
17th Jan 20177:00 amRNSAppointment of Giulio Cerroni as CEO
16th Jan 20172:00 pmRNSAnnual Report and Accounts and Notice of AGM
13th Jan 20173:25 pmRNSHolding(s) in Company
12th Jan 20172:56 pmRNSHolding(s) in Company
4th Jan 20173:43 pmRNSIssue of 590,093 Deferred Consideration Shares
23rd Dec 20167:00 amRNSBuyback and Cancellation of Deferred Shares
20th Dec 20167:00 amRNSFull Year Results
16th Nov 20167:00 amRNSParticipation in major EU partnership (ROADMAP)
21st Oct 20167:00 amRNSPre-Close Trading Update
20th Oct 20167:00 amRNS$1.2m contract with new global pharma customer
19th Oct 20167:00 amRNSIXICO presents at CAMD regulatory workshop
10th Oct 20167:00 amRNSEUR1m funding as a partner in major EU consortium
3rd Oct 20167:00 amRNSAppointment of Shore Capital as Nominated Adviser
3rd Oct 20167:00 amRNSAppointment of Shore Capital
26th Sep 20165:14 pmRNSDirector/PDMR Shareholding
26th Sep 20161:58 pmRNSExercise of Share Options
16th Sep 20167:00 amRNSBoard changes
13th Sep 20167:00 amRNSPresentation of Assessa® PML at ECTRIMS
29th Jul 201610:25 amRNSWeb-Based Technology Improves Paediatric ADHD Care
7th Jun 20167:00 amRNSHalf Yearly Report to 31 March 2016
2nd Jun 20167:00 amRNSCygnus joins Dementias Platform UK
4th Apr 20167:00 amRNSConsortium and Five Year Contract

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.